Literature DB >> 6745218

Effect of viloxazine on serum carbamazepine levels in epileptic patients.

F Pisani, M C Narbone, A Fazio, P Crisafulli, G Primerano, A A D'Agostino, G Oteri, R Di Perri.   

Abstract

The present study describes the interaction between carbamazepine (CBZ) and viloxazine, a recently synthesized antidepressant agent. Seven epileptic patients on chronic anticonvulsant therapy showed a significant (p less than 0.005) increase in steady-state serum CBZ levels (from 8.1 +/- 2.5 SD to 12.1 +/- 2.5 SD micrograms/ml) when viloxazine (300 mg/day) was added to the therapy. The effect was associated with the appearance of mild CBZ intoxication. The symptoms of this intoxication (i.e., dizziness, ataxia, fatigue, drowsiness) disappeared rapidly, and serum CBZ levels decreased to the basal values, when viloxazine administration was stopped.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6745218     DOI: 10.1111/j.1528-1157.1984.tb03447.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction.

Authors:  F Pisani; A Fazio; C Artesi; M Russo; R Trio; G Oteri; E Perucca; R Di Perri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-02       Impact factor: 10.154

2.  Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.

Authors:  F Pisani; A Fazio; E Spina; C Artesi; B Pisani; M Russo; R Trio; E Perucca
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 3.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 4.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

6.  Viloxazine and anticonvulsants.

Authors:  M R Trimble
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

7.  Carbamazepine-viloxazine interaction in patients with epilepsy.

Authors:  F Pisani; A Fazio; G Oteri; E Perucca; M Russo; R Trio; B Pisani; R Di Perri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-10       Impact factor: 10.154

8.  Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats.

Authors:  W Daniel; L Janczar; L Danek; W Legrum; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

9.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.